Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
暂无分享,去创建一个
E. Kimby | J. Gribben | F. Bosch | N. Heerema | M. Gobbi | O. Frankfurt | M. Hallek | A. Chanan-Khan | S. Stilgenbauer | D. Mahadevan | M. Sekeres | A. Bühler | C. Wendtner | S. Coutre | R. Furman | D. Hurd | A. Ferrajoli | L. Dreisbach | P. Hillmen | L. Uharek | A. Bloor | Jennie Zhang | Sheetal Shah | L. M. Moutouh-de Parseval | Sheetal H Shah | L. Moutouh-de Parseval
[1] M. Czuczman,et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response , 2012, Cancer.
[2] K. Markou,et al. National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .
[3] M. Hallek,et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Briones,et al. Emerging therapies for patients with advanced chronic lymphocytic leukaemia. , 2009, Blood reviews.
[5] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[6] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[7] Z. Estrov,et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.
[8] Claire Dearden,et al. Disease-specific complications of chronic lymphocytic leukemia. , 2008, Hematology. American Society of Hematology. Education Program.
[9] J. Zeldis,et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Thomas S. Lin,et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.
[11] H. Kantarjian,et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy , 2007, Leukemia & lymphoma.
[12] M. Czuczman,et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Jagannath,et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.
[14] M. Cairo,et al. Tumour lysis syndrome: new therapeutic strategies and classification , 2004, British journal of haematology.
[15] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[16] R. Figlin,et al. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High‐grade non‐Hodgkin's lymphoma and chronic lymphocytic leukemia , 1999, American journal of hematology.
[17] B. Cheson,et al. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] V. Diehl,et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) , 1998, Annals of Hematology.
[19] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.